Key features and details
- Rabbit polyclonal to EKLF / KLF1
- Suitable for: WB, Indirect ELISA
- Isotype: IgG
Product nameAnti-EKLF / KLF1 antibody
See all EKLF / KLF1 primary antibodies
DescriptionRabbit polyclonal to EKLF / KLF1
Tested applicationsSuitable for: WB, Indirect ELISAmore details
Synthetic peptide corresponding to C terminal residues of KLF1 (Erythroid krueppel like transcription factor) (Mouse)
Storage instructionsShipped at 4°C. Store at -20°C. Stable for 12 months at -20°C.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: 50% Glycerol, PBS
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab56011 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 1 µg/ml. Predicted molecular weight: 38 kDa. Incubate for 2 hours. This antibody has been tested in Western blot against the recombinant peptide used as an immunogen. We have no data on detection of endogenous protein.|
|Indirect ELISA||Use at an assay dependent concentration.|
FunctionTranscription regulator of erythrocyte development that probably serves as a general switch factor during erythropoiesis. Is a dual regulator of fetal-to-adult globin switching. Binds to the CACCC box in the beta-globin gene promoter and acts as a preferential activator of this gene. Furthermore, it binds to the BCL11A promoter and activates expression of BCL11A, which in turn represses the HBG1 and HBG2 genes. This dual activity ensures that, in most adults, fetal hemoglobin levels are low. Able to activate CD44 and AQP1 promoters. When sumoylated, acts as a transcriptional repressor by promoting interaction with CDH2/MI2beta and also represses megakaryocytic differentiation.
Tissue specificityExpression restricted to adult bone marrow and fetal liver. Not expressed in myeloid nor lymphoid cell lines.
Involvement in diseaseDefects in KLF1 are the cause of congenital dyserythropoietic anemia type 4 (CDA4) [MIM:613673]. It is a blood disorder characterized by ineffective erythropoiesis and hemolysis resulting in anemia. Circulating erythroblasts and erythroblasts in the bone marrow show various morphologic abnormalities. Affected individuals with CDA4 also have increased levels of fetal hemoglobin.
Sequence similaritiesBelongs to the krueppel C2H2-type zinc-finger protein family.
Contains 3 C2H2-type zinc fingers.
modificationsAcetylated; can be acetylated on both Lys-274 and Lys-288. Acetylation on Lys-274 (by CBP) appears to be the major site affecting EKLF transactivation activity.
Sumoylated; sumoylation, promoted by PIAS1, leads to repression of megakaryocyte differentiation. Also promotes the interaction with the CDH4 subunit of the NuRD repression complex.
Phosphorylated primarily on serine residues in the transactivation domain. Phosphorylation on Thr-23 is critical for the transactivation activity.
Cellular localizationNucleus. Colocalizes with SUMO1 in nuclear speckles.
- Information by UniProt
- CDAN4 antibody
- EKLF antibody
- EKLF PEN antibody
ab56011 has been referenced in 1 publication.
- Porcu S et al. Klf1 affects DNase II-alpha expression in the central macrophage of a fetal liver erythroblastic island: a non-cell-autonomous role in definitive erythropoiesis. Mol Cell Biol 31:4144-54 (2011). WB, ChIP ; Mouse . PubMed: 21807894